Novartis: Prostatic Neoplasms trials
The registry lists 82 Prostatic Neoplasms studies with Novartis as lead sponsor. 13 are open to participants now and 12 have results posted.
Phase 1 27Phase 2 26Phase 3 14Phase 4 14No phase 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic Castration Resistant Prostate Cancer PatientsNot yet recruitingNCT07928037
- A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerRecruitingNCT07570979Phase 1
- PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide TetraxetanRecruitingNCT07484269
- Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)RecruitingNCT07290270
- Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsRecruitingNCT07288359Phase 1/2
- A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruitingNCT07226986Phase 1/2
- An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)RecruitingNCT07206056Phase 1/2
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCRecruitingNCT06855277Phase 3
- Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyRecruitingNCT06780670Phase 2/3
- Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate CancerRecruitingNCT06517719
- Post Marketing Study on Pluvicto in KoreaRecruitingNCT06514521
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.RecruitingNCT05939414Phase 3
- Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerRecruitingNCT05803941Phase 4
- Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors DetectionCompletedNCT04838626Phase 2/3Results posted
- Study of Diagnostic Performance of [18F]CTT1057 in BCRCompletedNCT04838613Phase 3Results posted
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Active, not recruitingNCT04720157Phase 3Results posted
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerCompletedNCT04689828Phase 3Results posted
- [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)TerminatedNCT03724253Phase 2Results posted
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate CancerCompletedNCT03511664Phase 3Results posted
- 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)CompletedNCT03490032Phase 1/2Results posted
- Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapyTerminatedNCT03042312Phase 2Results posted
- Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorCompletedNCT01459653Results posted
- Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate CancerCompletedNCT00667862Phase 2Results posted
- Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate CancerCompletedNCT00427999Phase 2Results posted
- Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate CancerCompletedNCT00242567Phase 3Results posted
- Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsWithdrawnNCT07570966Phase 1/2
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated PatientsCompletedNCT07477756
- A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617CompletedNCT07450157
- A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate CancerActive, not recruitingNCT07174063Phase 1
- Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT07093801
- A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT07047118Phase 2
- An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Active, not recruitingNCT06991556Phase 2
- An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCActive, not recruitingNCT06894511Phase 2
- Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPCWithdrawnNCT06881823Phase 1/2
- A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) StudyActive, not recruitingNCT06531499Phase 1
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.TerminatedNCT06379217Phase 1
- Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLTActive, not recruitingNCT05983198Phase 1
- A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCActive, not recruitingNCT05849298Phase 2
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPCCompletedNCT05670106Phase 2
- A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate CancerActive, not recruitingNCT05658003Phase 2
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in JapanCompletedNCT05114746Phase 2
- A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate CancerActive, not recruitingNCT05067140Phase 1/2
- 177Lu-PSMA-617 Managed Access Program for mCRPC PatientsNo longer availableNCT04825652
- Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate CancerActive, not recruitingNCT04597411Phase 1
- 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate CancerTerminatedNCT03490838Phase 1
- Phase 1 of EC1169 In Patients With Recurrent MCRPCCompletedNCT02202447Phase 1
- A Study of Oral CFG920 in Patients With Castration Resistant Prostate CancerTerminatedNCT01647789Phase 1
- Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate CancerCompletedNCT01646684Phase 1
- Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) PatientsCompletedNCT01634061Phase 1
- A Phase I Study of LFA102 in Japanese PatientsCompletedNCT01610050Phase 1
- Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast CancerCompletedNCT01338831Phase 1
- Glivec in Prostate Cancer Patients With Rising PSA Following Radical ProstectomyCompletedNCT01316458Phase 2
- Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed ConditionsCompletedNCT00960310Phase 1
- Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting ConditionsCompletedNCT00959335Phase 1
- A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone MetastasesTerminatedNCT00757757Phase 1/2
- A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck CancerCompletedNCT00670553Phase 1
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate CancerCompletedNCT00663832Phase 1
- Safety of LBH589 Alone and in Combination With IV Docetaxel and PrednisoneTerminatedNCT00493766Phase 1
- Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone MetastasesCompletedNCT00434447Phase 4
- Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone MetastasesCompletedNCT00434317Phase 4
- Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and PrednisoneTerminatedNCT00419536Phase 1
- Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate CancerCompletedNCT00411528Phase 2
- Maintaining Bone Strength in Men With Prostate CancerTerminatedNCT00391950Phase 3
- Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate CancerCompletedNCT00391690Phase 4
- Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate CancerCompletedNCT00375648Phase 3
- Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast CancerCompletedNCT00334139Phase 4
- Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.TerminatedNCT00258765Phase 2
- Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone MetastasesCompletedNCT00242554Phase 4
- Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone MetastasisCompletedNCT00237159Phase 4
- Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone OrchiectomyCompletedNCT00237146Phase 4
- Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate CancerCompletedNCT00219271Phase 4
- Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone MetastasesCompletedNCT00219219Phase 4
- Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone TherapyCompletedNCT00172055Phase 3
- A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as BisphosphonatesCompletedNCT00172016Phase 4
- The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting OsteoporosisCompletedNCT00171639Phase 3
- Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer PatientsCompletedNCT00166725Phase 2
- A Prostate Cancer Study in Men Undergoing Androgen Deprivation TherapyCompletedNCT00087659Not applicable
- The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation TherapyCompletedNCT00063609Phase 4
- Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone MetastasisCompletedNCT00035997Phase 4
- EPO906 Therapy in Patients With Prostate CancerCompletedNCT00035113Phase 2
- Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone LesionsCompletedNCT00029224Phase 4
- Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No SymptomsTerminatedNCT00005073Phase 3